Skip to main content

Table 3 Comparison between COVID-19 patients with cancer and without cancer

From: Clinical features and death risk factors in COVID-19 patients with cancer: a retrospective study

Clinical features All patients (n = 309) Non-cancer patients (n = 206) Cancer patients (n = 103) P-value
Age 66.0 (20.0–95.0) 66.00 (20.00–95.00) 66.0 (24.0–90.0) 0.948
Gender     0.810
 Female 138 (44.7%) 91 (44.1%) 47 (45.6%)  
 Male 171 (55.3%) 115 (55.8%) 56 (54.4%)  
Comorbidities     
 Diabetes 37 (11.9) 23 (11.1%) 14 (13.6%) 0.579
 Hypertension 96 (31.0%) 59 (28.6%) 37 (35.9%) 0.195
 Heart disease 41 (13.2) 30 (14.5%) 11 (10.7%) 0.379
Symptoms     
 Fever 234 (74.7%) 161 (78.1) 73 (70.9%) 0.163
 Cough 207(66.9%) 137 (66.5%) 70 (68.0%) 0.898
 Dyspnea 45 (14.6%) 21 (10.2%) 24 (23.3%) 0.003
 Vomiting 10 (3.2%) 5 (2.4%) 5 (4.9%) 0.310
 Diarrhoea 17 (5.5) 10 (4.8%) 7 (6.8%) 0.597
Severity     0.520
 Non-severe 209 (67.6%) 142 (68.9%) 67 (65%)  
 Severe 100 (32.4%) 64 (31%) 36 (35%)  
Clinical outcome     0.028
 Survivor 288 (93.2%) 197 (95.6%) 91 (88.3%)  
 Non-survivor 21 (6.8%) 9 (4.4%) 12 (11.7%)  
Laboratory findings     
 WBC (× 109/L) 5.50 (0.80–28.20); n = 306 5.60 (0.80–28.2); n = 206 5.29 (1.90–25.10); n = 100 0.381
 Neutrophil (× 109/L) 3.25 (0.44–26.07); n = 306 3.23 (0.44–26.07); n = 206 3.49 (0.67–22.40); n = 100 0.164
 Lymphocyte (× 109/L) 1.41 (0.60–3.50); n = 306 1.54 (0.60–3.50); n = 206 1.06 (0.22–2.89); n = 100  < 0.001
 NLR 2.28 (0.20–62.12); n = 306 2.11 (0.20–62.12); n = 206 2.93 (0.64–32.23); n = 100  < 0.001
 Monocytes (× 109/L) 0.48 (0.03–1.16); n = 278 0.50 (0.03–1.16); n = 206 0.43 (0.11–1.11); n = 72 0.040
 Eosnophils (× 109/L) 0.11 (0.00–0.90); n = 278 0.12 (0.00–0.72); n = 206 0.07 (0.00–0.90); n = 72  < 0.001
 Basophils (× 109/L) 0.03 (0.00–0.11); n = 278 0.03 (0.00–0.08); n = 206 0.02 (0.00–0.11); n = 72 0.076
 RBC (× 1012/L) 3.93 (1.17–5.77); n = 279 3.93 (1.17–5.60); n = 206 3.95 (2.03–5.77); n = 73 0.406
 HB (g/L) 120.00 (53.00–166.00); n = 279 120.50 (53.00–166.00); n = 206 116.00 (68.00–154.00); n = 73 0.074
 PLT (× 109/L) 209.50 (4.00–443.00); n = 278 213.00 (4.00–443.00); n = 206 203.00 (53.00–431.00); n = 72 0.120
 CRP (mg/L) 2.27 (0 .01–280.32); n = 251 2.16 (0.01–268.60); n = 161 2.52 (0.14–280.32); n = 90 0.147
 ALT (U/L) 21.67 (4.50–239.70); n = 301 23.35 (5.30–239.70); n = 204 19.17 (4.50–131.20); n = 97 0.047
 AST (U/L) 21.55 (9.60–502.40); n = 260 21.51 (9.60–502.40); n = 176 21.70 (10.00–147.20); n = 84 0.374
 Total protein (g/L) 65.5 (32.70–87.58); n = 276 65.81 (32.70–81.6); n = 205 64.99 (53.70–87.58); n = 71 0.528
 Albumin (g/L) 37.30 (18.3–48.00); n = 276 37.36 (18.30–45.55); n = 205 37.29 (23.60–48.00); n = 71 0.723
 Globulin (g/L) 27.73 (14.40–46.24); n = 276 27.70 (14.40–45.91); n = 205 28.00 (17.31–46.24); n = 71 0.417
 A/G 1.33 (0.39–2.65); n = 276 1.33 (0.70–2.65); n = 205 1.30 (0.39–2.20); n = 71 0.338
 Total bilirubin (umol/L) 10.00 (4.20–415.70); n = 274 9.76 (4.20–415.70); n = 204 10.32 (4.20–44.58); n = 70 0.514
 Direct Bilirubin (umol/L) 2.50 (0.00–326.70); n = 274 2.50 (0.00–326.70); n = 204 2.71 (0.00–23.90); n = 70 0.412
 Indirect bilirubin (umol/L) 7.18 (2.69–89.01); n = 274 7.17 (2.69–89.01); n = 204 7.39 (2.99–26.42); n = 70 0.883
 BUN (umol/L) 4.88 (2.23–36.08); n = 272 4.93 (2.23–36.08); n = 204 4.67 (2.68–29.61); n = 68 0.471
 Creatinine (umol/L) 60.00 (13.25–345.35); n = 273 60.87 (26.77–243.40); n = 203 57.72 (13.25–345.35); n = 70 0.509
 Uric acid (umol/L) 281.63 (69.00–600.56); n = 273 286.02 (69.00–600.56); n = 204 268.01 (100.00–575.95); n = 69 0.274
 ALP (U/L) 71.10 (31.90–493.30); n = 272 71.12 (31.90–366.10); n = 202 71.10 (42.59–493.30); n = 70 0.461
 γ-GT (U/L) 26.50 (7.64–263.6); n = 273 26.50 (7.64–242.2); n = 203 26.47 (8.15–263.60); n = 70 0.813
 CK (U/L) 44.31 (10.90–1210.00); n = 229 43.20 (11.00–1210.00); n = 174 48.40 (10.90–195.90); n = 55 0.084
 LDH (U/L) 175.35 (2.17–1489.89); n = 270 174.10 (99.90–489.89); n = 201 179.90 (2.17–761.70); n = 69 0.686
 ɑ-HBDH (U/L) 130.30 (79.66–1028.00); n = 267 129.80 (79.66–1028.00); n = 201 133.59 (87.75–701.40); n = 66 0.511
 D-dimer (mg/L) 0.44 (0.01−27.94); n = 172 0.44 (0.01−6.91); n = 127 0.43 (0.02–27.94); n = 45 0.498
 NT-proBNP (U/L) 43.94 (0.01–35,000.00); n = 102 51.61 (0.01–35,000.00); n = 80 30.77 (0.01–515.18); n = 22 0.503
 Procalcitonin (ng/ml) 0.045 (0.01–87.04); n = 200 0.042 (0.01–87.04); n = 144 0.05 (0.02–0.90); n = 56 0.231
 IL-6 (pg/ml) 3.20 (1.50–5000.00); n = 189 3.0 (1.50–5000.00); n = 139 3.64 (1.50–3392.00); n = 50 0.099
  1. WBC white blood cell, NLR leukocyte to lymphocyte ratio, RBC red blood cell, HB hemoglobin, PLT platelet, CRP C-reactive protein, ALT alanine transaminase, AST aspartate transaminase, A/G albumin to globulin ratio, BUN blood urea nitrogen, ALP alkaline phosphatase, γ-GT gamma-glutamyl transpeptidase, CK creatine kinase, CKMB MB isoenzyme of creatine kinase, LDH lactate dehydrogenase, α-HBDH alpha-hydroxybutyric dehydrogenase, NT-proBNP N-terminal pro brain natriuretic peptide, IL-6 interleukin-6